演題抄録

International Session(Oral)

開催概要
開催回
第51回・2013年・京都
 

Doc plus FOLFOX4 as adjuvant chemotherapy for stage Ib-IV (M0) gastric cancer

演題番号 : ISO1-4

[筆頭演者]
Chunxia Du:1 
[共同演者]
Jinwan Wang:1、Aiping Zhou:1、Jing Huang:1、Honggang Zhang:1

1:Med Oncol Dept, CICAMS, China

 

Purpose The feasibility and efficacy of 3-drug combination regimen as adjuvant chemotherapy were investigated for radically resected gastric cancer patients.Patients and Methods From January 2006 to June 2011, 127 Chinese patients with stage Ib-IV (M0) (AJCC V6) gastric carcinoma were included. All patients received a total or subtotal gastrectomy with at least D1 lymph node dissection. Docetaxel was administered at 40mg/m2 on day 1 every 2 weeks, plus standard FOLFOX4 regimen for maximum 12 cycles.Results With a median follow-up time of 29.2 months, 55 patients developed relapses or a second primary tumor. Common sites of first relapse were peritoneum (16.5%) and lymth nodes(15.0%). The median disease free survival (DFS) is 48.8 months, and the median overall survival has not yet been reached. The treatments were generally well tolerated. The most frequent grade 3-4 toxicity was neutropenia (47.6%). Other grade 3-4 toxicities included decreased appetite (18.3%), nausea (12.7%), vomiting(6.3%), peripheral sensory neuropathy(5.6%), diarrhea(4.8%) and thrombocytopenia(4.8%).Conclusion The 3-drug regimen with docetaxel plus FOLFOX4 was feasible as adjuvant chemotherapy for gastric cancer patients in China. The preliminary efficacy is encouraging.

前へ戻る